Opus Genetics IRD Issuance of common stock and pre-funded warrants in connection with the March 2025 offering and private placement
Issuance of common stock and pre-funded warrants in connection with the March 2025 offering and private placement at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept ird:StockIssuedDuringPeriodValueOfPrivateOfferingAndPrivatePlacement.
The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opus Genetics's issuance of common stock and pre-funded warrants in connection with the march 2025 offering and private placement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opus Genetics's issuance of common stock and pre-funded warrants in connection with the march 2025 offering and private placement?
- Opus Genetics (IRD) reported issuance of common stock and pre-funded warrants in connection with the march 2025 offering and private placement of $5.98M in Q1 2025.
- What does issuance of common stock and pre-funded warrants in connection with the march 2025 offering and private placement mean?
- Captures the proceeds from the sale of common stock and warrants through private placements, which are typically sold to institutional or accredited investors outside of public markets. This is a key indicator of a company's ability to secure targeted funding from specific investor groups.